Novo Nordisk Bets $1.46 Billion on Molecular Glues in Strategic Collaboration with Neomorph

Feb 27, 2024 12:00 CST Updated 12:00

Neomorph

Molecular Glue Drug Developer

Novo Nordisk

Insulin Developer and Manufacturer

On February 26, Neomorph announced a collaboration and license agreement with Novo Nordisk to engage in multi-target collaboration aimed at discovering novel molecular glue degraders for cardiometabolic and rare diseases. Potential dealTotalAmount: 1.46 billion US dollars.

Neomorph will lead the discovery and preclinical activities for selected targets, while Novo Nordisk has the exclusive right to further clinically develop and commercialize these compounds. Both parties will leverage Neomorph's proprietary molecular glue discovery platform combined with Novo Nordisk's extensive expertise in cardiometabolic and rare diseases to develop transformative therapeutic approaches.

Neomorph, Inc. was founded in 2020 and is backed by Deerfield Management Company. The company addresses critical issues in human health by discovering novel therapies targeting "undruggable" targets.

Molecular glue is a hot track in the field of protein degradation, and has already attracted the attention of many giants. In addition to Novo Nordisk, BMS also announced the latest cooperation this month, using generative AI technology to accelerate the discovery of molecular glue (recommended reading:$674 Million! BMS Doubles Down on AI Drug Discovery, This Time Targeting Molecular Glues）。

References:

https://neomorph.com/index.html#news

Recommended Reading

100 New Targets| 2023 Annual
Nature Breakthrough: 1+1>2, A New Protein Degrader is Here……

PharmaCube Pro

New Targets, New Technologies, New Therapies

Business Cooperation: 13502093012

Media cooperation: 15895423126

Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article.For reprint, please leave a message to the WeChat Official Account backend or send a message, and indicate the name and ID of the official account.

Disclaimer: The information in this WeChat article is for general reference only and should not be used directly as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.